Table 1

 Spinal mobility measures after extended etanercept exposure*

RCT trial arm
EtanerceptPlacebo
*Data presented are mean (SE) unless otherwise noted; †total of 96 weeks of etanercept: 24 weeks in RCT and 72 weeks of open label treatment; ‡total of 72 weeks of etanercept: 24 weeks of placebo in RCT and 72 weeks of etanercept open label.
Occiput to wall measurement
RCT baseline5.4 (0.5) (n = 128)5.0 (0.6) (n = 129)
Week 96 (72 weeks of open label)4.0 (0.6)† (n = 95)4.6 (0.7)‡ (n = 105)
Improvement1.5 (0.3)0.3 (0.4)
Median improvement00
Chest expansion
RCT baseline3.4 (0.2) (n = 128)3.2 (0.2) (n = 129)
Week 96 (72 weeks of open label)4.0 (0.2)† (n = 95)3.5 (0.2)‡ (n = 105)
Improvement0.7 (0.2)0.2 (0.2)
Median improvement (range)0.50
Modified Schober’s index
RCT baseline3.1 (0.2) (n = 128)3.0 (0.1) (n = 129)
Week 96 (72 weeks of open label)3.5 (0.2)† (n = 95)3.2 (0.1)‡ (n = 105)
Improvement0.5 (0.1)0.2 (0.1)
Median improvement0.50.3